Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers
Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers
复制标题
DOI：
10.3945/ajcn.2008.27004
复制
发表时间：
2009-05-01
影响因子：
7.1
通讯作者：
Koerfer, Reiner
中科院分区：
文献类型：
--
作者：
Zittermann, Armin;Frisch, Sabine;Koerfer, Reiner
背景：高血液浓度的甲状旁腺激素和低浓度的维生素 D 代谢物 25-羟基维生素 D [25( OH) D] 和骨化三醇被认为是新的心血管疾病风险标志物。然而，也有证据表明骨化三醇会增加脂肪生成并减少脂肪分解。目的：我们研究了维生素 D 对体重减轻以及超重受试者中传统和非传统心血管疾病风险标志物的影响。设计：平均 25(OH)D 浓度为 30 nmol/L (12 ng/mL) 的健康超重受试者 (n = 200) 以双盲方式接受维生素 D (83 mu g/d) 或安慰剂， 12 个月，同时参加减肥计划。结果：补充维生素 D (-5.7 +/- 5.8 kg) 或安慰剂 (-6.4 +/- 5.6 kg) 对体重减轻没有显着影响。然而，维生素 D 组的平均 25(OH)D 和骨化三醇浓度分别增加了 55.5 nmol/L 和 40.0 pmol/L，但安慰剂组仅分别增加了 11.8 nmol/L 和 9.3 pmol/L (P < 0.001)，而维生素 D 组的甲状旁腺激素血液浓度比安慰剂组下降更明显 (-26.5%)与 -18.7% 相比；P = 0.014）、甘油三酯（-13.5% 与 +3.0% 相比；P < 0.001）以及炎症标志物肿瘤坏死因子-α（-10.2% 与 -3.2% 相比；P = 0.049）。有益的生化作用与体重、脂肪量和性别的减少无关。然而，与安慰剂相比，补充维生素 D 也增加了 LDL 胆固醇浓度（+5.4% 与 -2.5% 相比；P < 0.001）。结论：结果表明，每天补充 83 微克维生素 D 不会对减肥产生不利影响，并且能够显着改善参加减肥计划的维生素 D 状态不足的超重受试者的多种心血管疾病风险标志物。该试验在 Clinical-Trials.gov 上注册为 NCT00493012。美国临床营养杂志 2009；89：1321-7。
Background: High blood concentrations of parathyroid hormone and low concentrations of the vitamin D metabolites 25-hydroxyvitamin D [25( OH) D] and calcitriol are considered new cardiovascular disease risk markers. However, there is also evidence that calcitriol increases lipogenesis and decreases lipolysis.Objective: We investigated the effect of vitamin D on weight loss and traditional and nontraditional cardiovascular disease risk markers in overweight subjects.Design: Healthy overweight subjects (n = 200) with mean 25(OH)D concentrations of 30 nmol/L (12 ng/mL) received vitamin D (83 mu g/d) or placebo in a double-blind manner for 12 mo while participating in a weight-reduction program.Results: Weight loss was not affected significantly by vitamin D supplementation (-5.7 +/- 5.8 kg) or placebo (-6.4 +/- 5.6 kg). However, mean 25(OH)D and calcitriol concentrations increased by 55.5 nmol/L and 40.0 pmol/L, respectively, in the vitamin D group but by only 11.8 nmol/L and 9.3 pmol/L, respectively, in the placebo group (P < 0.001), whereas a more pronounced decrease occurred in the vitamin D group than in the placebo group in blood concentrations of parathyroid hormone (-26.5% compared with -18.7%; P = 0.014), triglycerides (-13.5% compared with +3.0%; P < 0.001), and the inflammation marker tumor necrosis factor-alpha (-10.2% compared with -3.2%; P = 0.049). The beneficial biochemical effects were independent of the loss in body weight, fat mass, and sex. However, compared with placebo, vitamin D supplementation also increased LDL-cholesterol concentrations (+5.4% compared with -2.5%; P < 0.001).Conclusions: The results indicate that a vitamin D supplement of 83 mu g/d does not adversely affect weight loss and is able to significantly improve several cardiovascular disease risk markers in overweight subjects with inadequate vitamin D status participating in a weight-reduction program. This trial was registered at clinical-trials.gov as NCT00493012. Am J Clin Nutr 2009;89:1321-7.